$81.32
0.12% today
NYSE, Sep 04, 04:46 pm CET
ISIN
US28176E1082
Symbol
EW

Edwards Lifesciences Stock price

$81.22
+1.13 1.41% 1M
+9.83 13.77% 6M
+7.19 9.71% YTD
+12.47 18.14% 1Y
-7.47 8.42% 3Y
-4.47 5.22% 5Y
+58.30 254.29% 10Y
+77.57 2,125.21% 20Y
NYSE, Closing price Wed, Sep 03 2025
-0.55 0.67%

Key metrics

Basic
Market capitalization
$47.7b
Enterprise Value
$44.2b
Net debt
positive
Cash
$4.1b
Shares outstanding
587.9m
Valuation (TTM | estimate)
P/E
11.5 | 31.6
P/S
8.4 | 7.7
EV/Sales
7.8 | 7.2
EV/FCF
76.5
P/B
4.5
Financial Health
Equity Ratio
76.6%
Return on Equity
41.8%
ROCE
13.1%
ROIC
15.5%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$5.7b | $6.2b
EBITDA
$1.7b | $1.8b
EBIT
$1.6b | $1.7b
Net Income
$4.1b | $1.5b
Free Cash Flow
$577.9m
Growth (TTM | estimate)
Revenue
-1.1% | 13.3%
EBITDA
0.2% | 11.8%
EBIT
0.2% | 12.8%
Net Income
181.6% | -63.8%
Free Cash Flow
7.3%
Margin (TTM | estimate)
Gross
78.9%
EBITDA
30.6% | 29.7%
EBIT
27.9%
Net
73.0% | 24.5%
Free Cash Flow
10.2%
More
EPS
$7.1
FCF per Share
$1.0
Short interest
1.6%
Employees
16k
Rev per Employee
$340.0k
Show more

Is Edwards Lifesciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Edwards Lifesciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

43 Analysts have issued a Edwards Lifesciences forecast:

27x Buy
63%
15x Hold
35%
1x Sell
2%

Analyst Opinions

43 Analysts have issued a Edwards Lifesciences forecast:

Buy
63%
Hold
35%
Sell
2%

Financial data from Edwards Lifesciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
5,685 5,685
1% 1%
100%
- Direct Costs 1,201 1,201
7% 7%
21%
4,484 4,484
1% 1%
79%
- Selling and Administrative Expenses 1,881 1,881
4% 4%
33%
- Research and Development Expense 1,055 1,055
1% 1%
19%
1,740 1,740
0% 0%
31%
- Depreciation and Amortization 152 152
0% 0%
3%
EBIT (Operating Income) EBIT 1,588 1,588
0% 0%
28%
Net Profit 4,148 4,148
182% 182%
73%

In millions USD.

Don't miss a Thing! We will send you all news about Edwards Lifesciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Edwards Lifesciences Stock News

Positive
MarketBeat
3 days ago
In the world of healthcare stocks, a major innovation, new medical device, or successful drug treatment can cement a firm's position as a leader. Unfortunately, many firms chase after these goals and never achieve them.
Neutral
Business Wire
6 days ago
MADRID--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) welcomes the updated ESC/EACTS guidelines for valvular heart disease, which establish a simplified care pathway for all severe aortic stenosis (AS) patients, regardless of symptoms. The guidelines enable a proactive approach to disease management and underscore that intervention should be considered for asymptomatic patients, regardless o...
Neutral
Business Wire
16 days ago
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that it has executed an accelerated share repurchase agreement ("ASR") to repurchase $500 million of Edwards' common stock. With this transaction, Edwards has repurchased more than $800 million of shares in 2025. Under the terms of this ASR, Edwards will receive an initial delivery of approximately 5 million shares...
More Edwards Lifesciences News

Company Profile

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. Its portfolio includes technologies designed for nonsurgical replacement of heart valves. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The Critical Care portfolio products through hemodynamic monitoring system measures a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Head office United States
CEO Bernard Zovighian
Employees 15,800
Founded 1958
Website www.edwards.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today